{"entity":{"id":"maq-001","kind":"drug","name":"MAQ-001","aka":[],"tldr":"MAQ-001 is an experimental monoclonal antibody from MabQuest, in phase 1 trials for advanced solid tumours.","summary":"MAQ-001 is a monoclonal antibody (allosteric anti-PD-1) from MabQuest. An anti-PD-1 antibody that binds PD-1 at an allosteric site; it stops PD-1 from suppressing the CD28 co-receptor, independent of PD-L1 binding, and is meant to be combined with conventional anti-PD-1 and other checkpoint drugs. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT06514651 recruiting in France, alone and with ipilimumab. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"MabQuest: mabquest.co","url":"https://mabquest.co/what-we-do"},{"label":"MabQuest: mabquest.co","url":"https://mabquest.co/what-we-do"},{"label":"MabQuest: mabquest.co","url":"https://mabquest.co/what-we-do"},{"label":"MabQuest: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06514651"},{"label":"ClinicalTrials.gov: trials of MAQ-001","url":"https://clinicaltrials.gov/search?intr=MAQ-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":[],"companies":["mabquest"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06514651"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MAQ-001","modality":"Monoclonal antibody (allosteric anti-PD-1)","mechanism":"An anti-PD-1 antibody that binds PD-1 at an allosteric site; it stops PD-1 from suppressing the CD28 co-receptor, independent of PD-L1 binding, and is meant to be combined with conventional anti-PD-1 and other checkpoint drugs.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/maq-001/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"mabquest","kind":"company","name":"MabQuest","route":"/companies/mabquest/"}],"trial":[{"id":"nct06514651","kind":"trial","name":"MAQ-001 in Patients With Advanced Solid Tumors","route":"/trials/nct06514651/"}]}}